Eli Lilly's stock price target has been raised to $1,100 by BMO, reflecting confidence in the company's dominance in the obesity drug market. This is significant as it highlights the growing recognition of the potential for obesity treatments to transform healthcare and generate substantial revenue for Eli Lilly, positioning it as a leader in this emerging sector.

Starbucks has received an Outperform rating from BMO following its recent joint venture deal in China, a move that is expected to strengthen its market presence in one of the world's largest coffee markets. This partnership not only enhances Starbucks' growth potential but also reflects investor confidence in the company's strategy to expand its footprint in Asia. As the demand for coffee continues to rise in China, this deal could lead to increased sales and profitability for Starbucks, making it an exciting time for investors.

William Blair has upgraded Terns Pharmaceuticals' stock rating to 'Outperform', signaling confidence in the company's future performance. This upgrade is significant as it reflects positive market sentiment and could attract more investors, potentially boosting the stock price. Such ratings can influence trading decisions and highlight the company's growth prospects.